The NDIA is conducting information sessions, designed to help people with disability, as well as their families and carers, get ready for the National Disability Insurance Scheme that will commence in the Sydney Central and South Eastern Sydney areas on 1 July 2017. The information sessions are also a perfect opportunity to bring your questions along and have them answered by experienced NDIA staff members.
The International Alliance of ALS/MND Associations will host a one-day Allied Professionals Forum at the Westin Boston Waterfront, Boston, USA on 7 December 2017. This seminar, specifically for allied health and social care professionals, is held between the International Alliance Meeting (5-6 December) and the International Symposium on ALS/MND (8-10 December). The Allied Professionals Forum is an opportunity for health professionals
The Motor Neurone Disease Association is pleased to announce the publication of the first announcement and call for papers for the 28th International Symposium on ALS/MND that will be held in Boston, USA on 8-10 December 2017. The abstract deadline is 26 May 2017 with the online submission system opening in late March 2017.
ALSUntangled reviews alternative and off-label treatments (AOTs) for people with ALS (PALS). In their latest review they evaluate Acuscope therapy for ALS (in response to 395 requests). Acuscope, also known as Electro-Acuscope, is a device that can deliver very low amplitude (micro-Amp) electrical stimulation to muscle. The review found there is no clear mechanism of action that would be useful to PALS and that, following the ALSUntangled review of trials and cases, Acuscope could not be endorsed for use to slow, stop or reverse ALS progression. You can read the full paper here http://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1285468?needAccess=true and find our more about ALSuntagled here http://www.alsuntangled.com/
A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
